Q&A: Zeposia may be efficacious oral therapy for UC

Zeposia may be an efficacious new oral therapy option with a favorable risk-benefit profile for patients with ulcerative colitis.Bristol-Myers Squibb recently announced results from the pivotal phase 3 trial, True North, which assessed oral Zeposia (ozanimod, Bristol-Meyers Squibb) as an induction and maintenance therapy for adult patients with moderate to severe UC, according to a press releaseTruth North met the primary endpoints at week 52 and demonstrated statistically significant results for induction and maintenance in adults with UC. Healio Gastroenterology spoke with William J.Read More